Medicines Marketed by Bharat Serums & Vaccines Ltd

About Bharat Serums & Vaccines Ltd

Bharat Serums and Vaccines Ltd (BSV) is a leading Indian biopharmaceutical company that has been dedicated to improving health and saving lives through innovative treatments and cures since its establishment in 1971. With over 50 years of experience in the sector, BSV focuses on the development, manufacture, and marketing of injectable biological, pharmaceutical, and biotech products.

Headquartered in Mumbai, India, BSV has a significant presence both domestically and internationally, with its products being distributed to retail outlets and hospitals across India and exported to over 70 countries worldwide, including the Asia Pacific, the Russian Federation, CIS countries, Latin America, and Africa. The company's diverse product portfolio covers several critical therapeutic areas, including women's health, critical care, animal bites, plasma derivatives, monoclonals, neurology, nephrology, haematology, and urology.

Bharat Serums & Vaccines Ltd Products

BSV's product portfolio is particularly strong in women's health, with a focus on fertility hormones and post-pregnancy therapies. The company is also well-known for its products in the critical care segment and its innovative treatments for snake bites and other animal bites. With over 145 brands in its portfolio, BSV offers a wide range of high-quality products that cater to various unmet medical needs.

The company's commitment to innovation and patient-centric approach is evident in its dedicated Research & Development center in Mumbai, where over 100 scientists work on new treatments and drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products. BSV operates under the values of Transparency, Agility, Accountability, and Collaboration, which guide its mission to preserve, protect, and enhance the quality of life. The company's recent acquisition by Mankind Pharma in October 2024 marks a significant strategic move that aligns with Mankind's vision to expand into high-entry barrier areas, particularly in women's health and fertility drugs.